VTP-27999
/ AbbVie
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
November 27, 2025
Effects of Inhibitors of the Activity of the Circulating Renin-Angiotensin System on the Growth and Proliferation of Endometrial Cancer Cells.
(PubMed, Int J Mol Sci)
- "We then determined the effects of drugs that inhibit the action of renin (VTP-27999 and aliskiren) or angiotensin-converting enzyme (perindoprilat) or block the angiotensin II type 1 receptor (losartan and telmisartan). RAS inhibitors were most effective in Ishikawa cells, which had the highest levels of RAS expression. Therefore, levels of RAS expression in endometrial cancers might indicate the potential efficacy of RAS drugs."
Journal • Endometrial Cancer • Oncology • Solid Tumor
February 04, 2025
Vasoinhibin is generated by the Renin-Angiotensin System.
(PubMed, Endocrinology)
- "Further increase in PRL circulating levels by the dopamine D2 receptor blocker, sulpiride, enabled detection of 14 kDa vasoinhibin in D/R rats. Moreover, the incubation of PRL with plasma from D/R rats generated a 14 kDa vasoinhibin that was prevented by VTP-27999. These findings add renin to the list of PRL-cleaving proteases and introduce vasoinhibin as a putative RAS-mediated mechanism for regulating blood vessel growth and function."
Journal • Endocrine Disorders • CTSD • DRD2
1 to 2
Of
2
Go to page
1